supported by NIH R21EB026035(X.L.L.);NIH R21AI149312(C.E.C.,and X.L.L.);NSF CBET-1943696(X.L.L.);Penn State startup funding to X.L.L.
CRISPR/Cas-mediated genome editing in human pluripotent stem cells(hPSCs)offers unprecedented opportunities for developing in vitro disease modeling,drug screening and cell-based therapies.To efficiently deliver the C...